These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 34624734)

  • 1. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.
    Weleff J; Akiki TJ; Barnett BS
    J Psychoactive Drugs; 2023; 55(4):434-444. PubMed ID: 36218281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelic Drug Legislative Reform and Legalization in the US.
    Siegel JS; Daily JE; Perry DA; Nicol GE
    JAMA Psychiatry; 2023 Jan; 80(1):77-83. PubMed ID: 36477830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.
    Luoma JB; Chwyl C; Bathje GJ; Davis AK; Lancelotta R
    J Psychoactive Drugs; 2020; 52(4):289-299. PubMed ID: 32529966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
    Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
    Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
    Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R
    J Psychopharmacol; 2023 Sep; 37(9):876-890. PubMed ID: 37572027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
    Videira NB; Nair V; Paquet V; Calhoun D
    J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
    Hovmand OR; Poulsen ED; Arnfred S
    J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is needed for the roll-out of psychedelic treatments?
    Xenakis SN; Shannon SM
    Curr Opin Psychiatry; 2024 Jul; 37(4):277-281. PubMed ID: 38726805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
    Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT
    Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
    Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
    Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.